NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis

Company Overview

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software. This system is designed to assist neurosurgeons in procedures such as epilepsy monitoring and deep brain stimulation planning by providing real-time, high-fidelity recordings of neuronal activity. NeuroOne also supports research partnerships with leading academic medical centers to explore applications of its technology in movement disorders and neurological disorders.

Founded as a spin-out of Mayo Clinic research, NeuroOne has advanced its technology through rigorous preclinical studies and regulatory review. In September 2023, the U.S. Food and Drug Administration granted 510(k) clearance for the EVO™ intraoperative neuromonitoring system. The company is headquartered in Eden Prairie, Minnesota, and operates a research and development facility in the same region to drive continuous innovation.

Under the leadership of President and CEO Rajendra S. Singh, MD, a neurosurgeon with extensive clinical experience, NeuroOne is executing a commercial rollout of its platform across North America. The company is actively engaging with key opinion leaders, surgical centers, and research institutions to establish its technology as a new standard for neural interface procedures. Looking ahead, NeuroOne aims to expand its geographic footprint and pursue additional regulatory approvals to broaden clinical access to its solutions.

Key Stats

• Today's Range: $4.14 to $4.43
• 50-Day Range: $0.74 to $5.11
• 52-Week Range: $3.27 to $6.96
• Volume: 42,713 shs
• Average Volume: 44,048 shs
• Market Capitalization: $36.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.50
• Consensus Rating: Hold

NeuroOne Medical Technologies Stock Analysis - MarketRank™

NeuroOne Medical Technologies scored higher than 64% of companies evaluated by MarketBeat, and ranked 271st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

NeuroOne Medical Technologies has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NeuroOne Medical Technologies has a consensus price target of $13.50, representing about 208.6% upside from its current price of $4.38.

Amount of Analyst Coverage

NeuroOne Medical Technologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroOne Medical Technologies are expected to grow in the coming year, from ($0.72) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroOne Medical Technologies is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroOne Medical Technologies is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroOne Medical Technologies has a P/B Ratio of 5.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.85% of the float of NeuroOne Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 0.47, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroOne Medical Technologies has recently increased by 14.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroOne Medical Technologies does not currently pay a dividend.

Dividend Growth

NeuroOne Medical Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.24

News Sentiment

NeuroOne Medical Technologies has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for NeuroOne Medical Technologies this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for NMTC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $658,295.00 in company stock, which represents 1.7870% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, NeuroOne Medical Technologies insiders have bought 5,625.49% more of their company's stock than they have sold. Specifically, they have bought $669,997.00 in company stock and sold $11,702.00 in company stock.

Percentage Held by Insiders

11.80% of the stock of NeuroOne Medical Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.07% of the stock of NeuroOne Medical Technologies is held by institutions.

NMTC Stock Analysis - Frequently Asked Questions

How have NMTC shares performed this year?

NeuroOne Medical Technologies' stock was trading at $4.5480 on January 1st, 2026. Since then, NMTC stock has decreased by 3.8% and is now trading at $4.3750.

How were NeuroOne Medical Technologies' earnings last quarter?

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) issued its quarterly earnings results on Tuesday, February, 17th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The company had revenue of $2.89 million for the quarter, compared to analysts' expectations of $2.47 million. NeuroOne Medical Technologies had a negative trailing twelve-month return on equity of 119.92% and a negative net margin of 78.34%.
Read the conference call transcript.

When did NeuroOne Medical Technologies' stock split?

NeuroOne Medical Technologies shares reverse split on Wednesday, April 15th 2026.A 1-6 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2026. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

When did NeuroOne Medical Technologies IPO?

NeuroOne Medical Technologies (NMTC) raised $500,000 in an initial public offering on Wednesday, May 26th 2021. The company issued 10,000,000 shares at a price of $0.05 per share.

How do I buy shares of NeuroOne Medical Technologies?

Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroOne Medical Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroOne Medical Technologies investors own include Schwab US Large-Cap ETF (SCHX), NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Ford Motor (F), Meta Platforms (META) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 2/17/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NMTC
• CIK: 1500198
• Web: www.originalsourcemusic.com
• Phone: (952) 426-1383
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeuroOne Medical Technologies: $13.50
• High Price Target: $18.00
• Low Price Target: $9.00
• Potential Upside/Downside: +208.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.61 million
• Net Margins: -78.34%
• Pretax Margin: -78.33%
• Return on Equity: -119.92%
• Return on Assets: -78.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.41
• Quick Ratio: 5.09

Sales & Book Value

• Annual Sales: $12.10 million
• Price / Sales: 3.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.85 per share
• Price / Book: 5.15

Miscellaneous

• Outstanding Shares: 8,420,000
• Free Float: 7,427,000
• Market Cap: $36.84 million
• Optionable: Optionable
• Beta: 0.60